ӳ����ý

Nearly a decade ago, the FDA approved the drug lenalidomide to treat patients with deletion-5q myelodysplastic syndrome (del(5q) MDS), a cancer of the myeloid cells in the bone marrow that form several types of blood cells. In this condition, some bone marrow cells are missing a portion of chromosome 5 – hence, the “del(5q)” – on one copy of their genome (the human genome has two copies of each chromosome, one from each parent), and this deletion causes malignant cells to grow unchecked.

Four years ago, David Root talked with us about the fundamentals of RNA interference (RNAi) technology. But, since then, the group that Root oversees – ӳ����ý’s erstwhile RNAi Platform – has taken on a new identity: it’s now known as the Genetic Perturbation Platform (GPP).